These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34347881)

  • 1. Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.
    Cleary Y; Gertz M; Grimsey P; Günther A; Heinig K; Ogungbenro K; Aarons L; Galetin A; Kletzl H
    Clin Pharmacol Ther; 2021 Dec; 110(6):1547-1557. PubMed ID: 34347881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children.
    Cleary Y; Kletzl H; Grimsey P; Heinig K; Ogungbenro K; Silber Baumann HE; Frey N; Aarons L; Galetin A; Gertz M
    Clin Pharmacokinet; 2023 Jun; 62(6):891-904. PubMed ID: 37148485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e1-e2. PubMed ID: 34544108
    [No Abstract]   [Full Text] [Related]  

  • 4. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy.
    Sergott RC; Amorelli GM; Baranello G; Barreau E; Beres S; Kane S; Mercuri E; Orazi L; SantaMaria M; Tremolada G; Santarsiero D; Waskowska A; Yashiro S; Denk N; Fürst-Recktenwald S; Gerber M; Gorni K; Jaber B; Jacobsen B; Mueller L; Nave S; Scalco RS; Marzoli SB;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):54-65. PubMed ID: 33231373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
    Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
    Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
    Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
    Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.
    Poirier A; Weetall M; Heinig K; Bucheli F; Schoenlein K; Alsenz J; Bassett S; Ullah M; Senn C; Ratni H; Naryshkin N; Paushkin S; Mueller L
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00447. PubMed ID: 30519476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risdiplam for the treatment of spinal muscular atrophy].
    Vlodavets DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis.
    Pineda ED; To TM; Dickendesher TL; Shapouri S; Iannaccone ST
    Adv Ther; 2024 Jun; 41(6):2446-2459. PubMed ID: 38709394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Pharmacokinetic and CYP3A Drug-Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment.
    Yu J; Tang F; Ma F; Wong S; Wang J; Ly J; Chen L; Mao J
    Drug Metab Dispos; 2024 Jul; 52(8):765-774. PubMed ID: 38811156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
    Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT;
    Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
    Wu F; Krishna G; Surapaneni S
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
    Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risdiplam: A Review in Spinal Muscular Atrophy.
    Paik J
    CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.
    Chiriboga CA; Bruno C; Duong T; Fischer D; Mercuri E; Kirschner J; Kostera-Pruszczyk A; Jaber B; Gorni K; Kletzl H; Carruthers I; Martin C; Scalco RS; Fontoura P; Muntoni F;
    J Neurol; 2024 Aug; 271(8):4871-4884. PubMed ID: 38733387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
    Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
    J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J; Zhou D; Li Y; Khanh BH
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
    Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
    Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.